Cargando…
Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites
Nazartinib (EGF816, NZB) is a promising third-generation human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This novel irreversible mutant-selective EGFR inhibitor targets EGFR containing both the resistance mutation (T790M) and the activating mutations (L858R and Del19), while...
Autores principales: | Abdelhameed, Ali S., Attwa, Mohamed W., Kadi, Adnan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731747/ https://www.ncbi.nlm.nih.gov/pubmed/31598253 http://dx.doi.org/10.1098/rsos.190852 |
Ejemplares similares
-
Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry
por: Attwa, Mohamed W, et al.
Publicado: (2020) -
Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry
por: Kadi, Adnan A., et al.
Publicado: (2018) -
Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling
por: Attwa, Mohamed W., et al.
Publicado: (2019) -
A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment
por: Alrabiah, Haitham, et al.
Publicado: (2019) -
Profiling of in vivo, in vitro and reactive zorifertinib metabolites using liquid chromatography ion trap mass spectrometry
por: Al-Shakliah, Nasser S., et al.
Publicado: (2022)